Moreover, investigating alternative vasodilators—such as calcium channel blockers or phosphodiesterase inhibitors—or different doses of NTG-based topical agents, and potentially combination creams containing several drugs, may provide additional tools to enhance procedural success and safety in the expanding field of heart failure intervention. The gene discussed is OPA1; the disease is heart failure.